Halozyme Therapeutics (HALO) is a $9 billion biotech focused on oncology and boasting sales and profit growth of 29% and 46%, respectively, while trading a sub-11x forward P/E. HALO is focused on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback